In general, IV bisphosphonates are very well tolerated, and patients rarely require dose modification. In the comparative phase 3 trial of zoledronic acid and pamidronate in patients with breast ...

“In the present study, we used multiple complementary approaches to evaluate the possible effects of zoledronic acid on cellular senescence.” Zoledronic acid has been found to reduce fracture risk and ...

Researchers systematically consulted the Massachusetts General Hospital fracture liaison service for patients admitted to the orthopedics service with fragility fracture between February 2016 and ...

Dear Dr. Roach: For the last few years, I have been taking yearly Reclast infusions for osteoporosis, because I have trouble taking oral medications of any kind. The infusion was given in February ...

DEAR DR. ROACH: For the last few years, I have been taking yearly Reclast infusions for osteoporosis, because I have trouble taking oral medications of any kind. The infusion was given in February ...

Please provide your email address to receive an email when new articles are posted on . An annual infusion of zoledronic acid was associated with less bone loss in adults with acute spinal cord injury ...

Vancouver, British Columbia — A highly controlled retrospective analysis suggests that denosumab (Prolia) leads to greater reduction in fracture risk than does zoledronic acid (Reclast) among ...

Background: Aminobisphosphonates (ABPs) has a definite direct anti-tumour activity but a limited activity in vivo. Their molecular targets are still not completely defined. Therefore, we have studied ...

A treatment for osteoporosis delivered once a year is as effective as current monthly or weekly osteoporosis regimens at reducing the incidence of bone fractures, according to a new study led by a ...

Dear Dr. Roach: I am a 71-year-old woman who still works full-time as a teacher. I have osteoporosis and have had two bone scans. My latest scan showed a slight deterioration from the first two years ...